AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02281370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
Study NCT03357731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion
Study NCT03357731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion
Study NCT03357731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion
Study NCT01417195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle
Study NCT01417195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur
Study NCT01417195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Study NCT00338039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
Study NCT00338039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off.
Study NCT00338039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
Study NCT00338039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
Study NCT00338039 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
Study NCT04248101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Ligation
Study NCT04248101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Silver Nitrate
Study NCT04156971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Study NCT04156971 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stage-based lifestyle modification intervention
Study NCT04156971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-based lifestyle modification intervention
Study NCT04092712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CTP-543
Description: Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
Study NCT00677820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine
Description: Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
Study NCT00677820 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
Study NCT05246020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
Study NCT05246020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous chemotherapy
Description: Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
Study NCT01489670 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.01% ophthalmic solution
Description: Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
Study NCT02385981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stivax
Study NCT02015442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Study NCT03226145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Motility
Description: MRI sequence to assess colonic motility
Study NCT03226145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Resolution Manometry
Description: HRM of colon to assess motility
Study NCT03226145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
Study NCT03226145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butylbromide
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
Study NCT01365039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, daily disposable contact lens
Description: Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
Study NCT01365039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofLens daily disposable contact lens
Description: Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
Study NCT01203540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAABAK eyedrops
Study NCT01203540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline eyedrops
Study NCT01505348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overnight fast
Description: Overnight fast from 21:00 h
Study NCT00129766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: motavizumab (MEDI-524)
Description: Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
Study NCT00129766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: palivizumab
Description: Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
Study NCT01337856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene protocol
Description: Comparison of efficacy of 3 hand hygiene protocols
Study NCT04636827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+DTaP+HepA
Description: sIPV+DTaP+HepA at the age of 18 month old
Study NCT04636827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: sIPV at the age of 18 month old
Study NCT04636827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: DTaP at the age of 18 month old
Study NCT04636827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HepA
Description: HepA at the age of 18 month old
Study NCT01035099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;
Study NCT01035099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
Study NCT03411720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
Study NCT03411720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
Study NCT03411720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
Study NCT01361035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cancer risk communication skills training
Description: Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
Study NCT02938884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HidrateSpark Water Bottle
Description: HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
Study NCT00933673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asp, DXM, IFO, VP-16, DDP
Description: L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Study NCT05015075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation
Description: cardiac rehabilitation after pacemaker implantation
Study NCT05015075 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cardiac rehabilitation
Description: cardiac rehabilitation after pacemaker implantation
Study NCT01590940 — intervention group
Intervention type: PROCEDURE
Intervention: Open inguinal hernia repair with mesh
Study NCT02605187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
Study NCT02605187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 600mg po one time within 1 hour of delivery
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (low)
Description: Intrathecal morphine dose 50mcg
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (med)
Description: Intrathecal morphine dose 150mcg
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine (med)
Description: Intrathecal morphine dose 150mcg
Study NCT02605187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (high)
Description: Intrathecal morphine 300mcg
Study NCT02640833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
Study NCT02640833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
Study NCT01841411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + N-Acetyl cysteine
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
Study NCT01841411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
Study NCT02431065 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectus sheath block
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT02431065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT02431065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT02431065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT02431065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT02431065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study NCT03364244 — intervention group
Intervention type: DRUG
Intervention: Sildenafil
Description: \[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.
Study NCT01476475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine /lixisenatide Fixed Ratio Combination
Description: FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
Study NCT01476475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Study NCT01476475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
Study NCT01476475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
Study NCT01667770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decompression of Chiari malformation
Description: Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
Study NCT01908764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371 otic suspension
Study NCT03381235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin exercise
Description: Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
Study NCT00843388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolacton (hexalacton(R))
Description: Tablet Spironolacton 25 mg OD